Gilead, Merck plan to debut new daily HIV pills
Gilead and Merck together are developing what could be the first weekly HIV pill, but they are also each making an individual push for new daily drugs. The two companies separately reported findings...
View ArticleSarepta CEO Doug Ingram to step down
Sarepta CEO Doug Ingram is stepping down from his role by the end of the year, ending a brash tenure in which he brought several Duchenne muscular dystrophy products to market and later presided over ...
View ArticleJapan's Asahi Kasei to buy German biotech Aicuris for $920M
The Japanese conglomerate Asahi Kasei is adding a biotech to its sprawling business portfolio, agreeing to acquire a longstanding privately held German company. Asahi Kasei announced Thursday it has...
View ArticleLilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
The second head-to-head Phase 3 trial in a week between dueling metabolic drugs from Eli Lilly and Novo Nordisk was reported Thursday. Once again, the data went Lilly’s way. The latest data came from a...
View ArticleOrbiMed jumps to number one on the top 100 list of biotech venture investors
This year’s list of the top 100 venture investors in the life sciences offered a few surprises, including OrbiMed’s vault into the number one slot on the list — jumping from its fourth-place finish for...
View ArticleSalma Health raises $80M for its clinics to treat brain health
A clinic that wants to use AI to move mental health treatment beyond trial-and-error prescribing to more precise care based on patients’ health data has raised $80 million in Series A funding,...
View ArticleNovartis to build another radioligand factory; Germany steps up probe into...
Novartis is building a new 46,000-square-foot factory in Denton, TX. Construction will start this year and is expected to be operational in 2028. The new facility is a part of its ...
View ArticleProtagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Protagonist Therapeutics will soon receive a significant amount of cash. Protagonist will opt out of its profit-sharing deal with Takeda on a rare disease drug, the biotech announced Wednesday,...
View ArticleAtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug
Plus, news about Boehringer Ingelheim, Sitryx Therapeutics, Argenx, Palvella Therapeutics, Vir Biotechnology, Larimar Therapeutics, Bristol Myers Squibb and SystImmune: 📉 AtaiBeckley releases Phase 2a...
View ArticleWhy did my doctor push Grail’s dubious cancer test?
Last year, my primary care physician tried to sell me on Grail’s cancer-detecting blood test. As I approached my 30th birthday, I wanted to start taking better care of my health. A friend recommended a...
View ArticleViatris plans to lay off up to 10% of staff, discloses Indian factory fire
Viatris said it's planning to cut up to 10% of its global workforce in an effort to save up to $700 million a year. In its fourth-quarter earnings report, the generic drugmaker on Thursday also ...
View ArticleSenate hearing raises FDA-related concerns for new rare disease drugs
Rare disease advocates and senators said they want to see more consistency in the FDA’s approval process during an Aging Committee hearing Thursday that examined how the agency’s regulatory processes...
View ArticleBoehringer wins accelerated approval for first-line use of lung cancer drug
The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an...
View ArticleFDA probes internal Prasad complaints with outside help
The FDA has been using an outside investigator in a probe of workplace complaints against CBER Director Vinay Prasad, a source familiar with the matter told Endpoints News. Among complaints made...
View ArticleDoug Ingram’s force of will meets its match as Sarepta CEO plans to depart
Doug Ingram’s decision to step down as Sarepta’s CEO by year's end was a shocker, considering his never-say-die reputation. But after a terrible year and a tanking share price, Sarepta's next leader...
View ArticleDOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case
The US solicitor general is calling on the Supreme Court to reverse a decision that he says would undermine a pathway commonly used to bring new generic drugs to market. The case centers on the ...
View ArticleDoug Ingram’s uneven legacy at Sarepta; Merck splits human health business,...
→ Merck said this week that it would divide its human health business into two groups — an oncology business unit and a specialty, pharma & infectious diseases business unit — suggesting that ...
View ArticleNovo Nordisk’s ‘strategic conundrum’: How being anchored to the past could...
It’s possible to imagine a world in which Novo Nordisk remained a medium-to-large European pharma company, a little like Merck KGaA or Boehringer Ingelheim, ticking over for hundreds of years, quietly...
View ArticleInvestors are pumping money into AI tools for health insurers
In the past month, payer AI startups including Anterior, Daffodil Health and Alaffia Health all raised tens of millions in fresh venture funding as insurers strive to match hospitals and health systems...
View ArticleNovartis closes Avidity deal as rare heart disease spinout launches
Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for...
View ArticlePadcev-Keytruda combo delivers more positive data in bladder cancer
Researchers have rolled out another win for the Padcev-Keytruda combination, this time as a first treatment for a form of bladder cancer. It's the second recent win for the combo after last year's...
View ArticleGinkgo divests biosecurity arm; J&J's early prostate cancer data
⚠️ Ginkgo Bioworks' biosecurity deal: The company is selling its biosecurity unit to a "consortium of investors," which will operate it as a standalone business. In exchange, Ginkgo will get ...
View ArticleWuXi XDC makes an ADC linker deal with Earendil for up to $885M
WuXi Biologics' antibody-drug conjugate spinout WuXi XDC said on Friday that it will be working with Earendil Labs to develop new antibody drug conjugates. AI-driven biologics developer Earendil will...
View ArticleGenerate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug...
A leader of the next wave of AI-driven biotechs completed one of the industry's largest IPOs in years, raising about $400 million in a sale of shares that will begin trading Friday. Just minutes after ...
View Article